Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects

The immunosuppressive agents sirolimus and everolimus are sensitive CYP3A4 substrates with narrow therapeutic index. Ritonavir is a strong CYP3A inhibitor. A phase 1 study was conducted to evaluate the pharmacokinetics, safety, and tolerability of the co‐administration of sirolimus or everolimus wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zha, Jiuhong, Jiang, Qi, Yao, Betty B., Cohen, Daniel E., Carter, David C., Menon, Rajeev M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683076/
https://www.ncbi.nlm.nih.gov/pubmed/36416673
http://dx.doi.org/10.1002/prp2.1024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683076/
https://www.ncbi.nlm.nih.gov/pubmed/36416673
http://dx.doi.org/10.1002/prp2.1024

Ejemplares similares